Skip to main content
European Commission logo print header

Novel precision technological platforms to promote non-invasive early diagnosis, eradication and prevention of cancer relapse: proof of concept in the bladder carcinoma.

Descripción del proyecto

Una tecnología con una precisión novedosa para el diagnóstico temprano y la erradicación del carcinoma de vejiga urinaria

En el proyecto EDIT, financiado con fondos europeos, proponen una tecnología transformadora que combina elastografía por ultrasonidos de alta resolución e imagenología fotoacústica para la detección temprana y el tratamiento del cáncer de vejiga urinaria. Para llegar a la matriz extracelular de la vejiga, este método utiliza nanotubos de oro artificiales como antena fotoacústica, cuyas propiedades los convierten en un biomarcador exclusivo del carcinoma. Además de crear una plataforma de visualización, los nanotubos de oro también pueden utilizarse para terapias fototérmicas contra el cáncer. El diseño de EDIT facilitará la detección de zonas preneoplásicas y la erradicación altamente selectiva de las células. En última instancia, ofrecerá una validación preclínica en la detección temprana del cáncer de vejiga y un nanomedicamento contra el carcinoma de vejiga preinvasor.

Objetivo

Unmet clinical needs in the management of bladder cancer (BCa) are the prevention of tumor onset, relapse and progression, and therapy of the aggressive carcinoma in situ (Cis), requiring weekly treatments and endless follow-up, with a consequent poor quality of life and the highest cost per patient among all cancers. Therefore, public health programs crave for early BCa detection protocols, to improve performance in the management of this devastating disease. Here we propose an advanced transformative technology termed EDIT combining a novel high-resolution ultrasound elastography and photoacoustic imaging on the bladder instilled with targeted plasmonic gold sensors.
EDIT approach exploits the structural and mechanical properties of the bladder extracellular matrix (ECM) as a unique biomarker of the early onset/progression/relapse of carcinoma, through engineered novel gold nanorods (GNRs) used as intravesical photoacoustic antennas targeted at the ECM, generating an ad hoc visualization platform. GNRs will be further utilized as heat-releasing effectors at nanoscale for targeted cancer photo-thermal therapy. EDIT is designed to detect pre-neoplastic area and eradication of local areas at few cells resolution with high sensitivity and specificity.
We bring together a multi and transdisciplinary consortium capable to develop non-invasive and non-ionizing novel technology and preclinical validation for early prognosis of BCa and therapeutic nanomedicine against bladder Cis. Outcomes of EDIT will revolutionize the management of BCa with the introduction of sensing and effector nanotechnologies combined with non-invasive organ imaging with high resolution/definition by 3D ultrasound and photoacoustic imaging.
Structural and mechanical modification of the ECM is a common denominator for invasive breast, colorectal, prostate and bladder cancers. EDIT platforms will also pave the ways for the earlier management of other bladder-related pathologies and solid tumors.

Convocatoria de propuestas

H2020-FETOPEN-2016-2017

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-FETOPEN-1-2016-2017

Régimen de financiación

RIA - Research and Innovation action

Coordinador

OSPEDALE SAN RAFFAELE SRL
Aportación neta de la UEn
€ 1 146 963,75
Dirección
VIA OLGETTINA 60
20132 Milano
Italia

Ver en el mapa

Región
Nord-Ovest Lombardia Milano
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 1 146 963,75

Participantes (9)